|
gptkbp:instanceOf
|
gptkb:drug
antidepressant
|
|
gptkbp:approvalYear
|
1990
|
|
gptkbp:approvedBy
|
gptkb:Netherlands
|
|
gptkbp:ATCCode
|
N06AX11
|
|
gptkbp:availableOn
|
gptkb:tablet
oral solution
orodispersible tablet
|
|
gptkbp:brand
|
gptkb:Avanza
gptkb:Mirtabene
gptkb:Mirtazon
gptkb:Remeron
gptkb:Zispin
|
|
gptkbp:CASNumber
|
61337-67-5
|
|
gptkbp:contraindication
|
gptkb:monoamine_oxidase_inhibitors
hypersensitivity to mirtazapine
|
|
gptkbp:developedBy
|
gptkb:Organon
|
|
gptkbp:discoveredIn
|
1989
|
|
gptkbp:drugClass
|
noradrenergic and specific serotonergic antidepressant (NaSSA)
|
|
gptkbp:eliminationHalfLife
|
20–40 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C17H19N3
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Mirtazapine
|
|
gptkbp:interactsWith
|
gptkb:beer
gptkb:monoamine_oxidase_inhibitors
gptkb:benzodiazepines
other CNS depressants
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
antagonist of central presynaptic alpha-2 adrenergic receptors
antagonist of histamine H1 receptors
antagonist of serotonin 5-HT2 and 5-HT3 receptors
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patent
|
gptkb:US_Patent_4,062,848
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:riskFactor
|
gptkb:serotonin_syndrome
suicidal thoughts
agranulocytosis
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
constipation
dizziness
fatigue
weight gain
drowsiness
dry mouth
increased appetite
|
|
gptkbp:usedFor
|
gptkb:post-traumatic_stress_disorder
gptkb:major_depressive_disorder
insomnia
anxiety disorders
appetite stimulation
|
|
gptkbp:bfsParent
|
gptkb:Antidepressants
|
|
gptkbp:bfsLayer
|
6
|